FDA delays Discovery Labs approval

Discovery Labs has been dealt another blow in its quest to gain approval for Surfaxin, a treatment for premature infant respiratory distress syndrome. The FDA issued an Approvable Letter yesterday, saying that it needed more information on the drug before it could be approved. Discovery says it will review the letter and discuss its next steps with the FDA. The company did not provide details regarding what additional information the FDA is seeking. This is the third approvable letter issued for the drug.

- here's the release

Related Articles:
Discovery Labs to raise $25M
Discovery Labs to explore "strategic alternatives"
Discovery Labs pulls marketing app for Surfaxin
Discovery Labs shares sink on data demand

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.